Parecoxib
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Parecoxib: From Postoperative Pain to Migraine Disorder
One-Sentence Summary
Parecoxib is a selective COX-2 inhibitor (injectable prodrug of valdecoxib), long used as an adjunct for short-term postoperative pain management. The TxGNN model predicts it may be effective for Migraine Disorder, but this direction is currently supported by only 1 pilot comparative study and no registered clinical trials specifically targeting migraine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Parecoxib is not currently marketed in Taiwan (0 licenses on record); no approved indication text in the evidence pack |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L3 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known pharmacology, Parecoxib is a selective COX-2 inhibitor and prodrug of valdecoxib, historically used via IV/IM injection for acute postoperative pain due to its anti-inflammatory and analgesic properties.
The mechanistic link to migraine proposed by the model is that COX-2 inhibition reduces prostaglandin-mediated neurogenic inflammation in the trigeminovascular system, which theoretically could relieve acute migraine attacks. However, COX-2 is not a mainstream migraine treatment target — current standard-of-care relies on triptans and CGRP antagonists — so this remains a secondary, mechanistically plausible but clinically unproven pathway.
Notably, a related predicted indication in this same evidence pack, “headache disorder” (rank 5, same L3 evidence level), shares this identical mechanistic rationale, but the clinical trials retrieved under that indication are almost all postoperative/procedural pain studies (graded “C” relevance), not headache-specific trials — reinforcing that the existing evidence base is adjacent rather than direct.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21996647 | 2011 | Comparative Study | Clinical Neuropharmacology | Pilot study comparing oral rizatriptan (10mg), IV parecoxib (40mg), and subcutaneous sumatriptan for acute migraine attack treatment |
EU Market Information
Parecoxib currently has no marketing authorization on record in Taiwan (0 licenses; market status: Not Marketed). No approved indication or product information is available from the regulatory dataset.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: Taiwan label warnings/contraindications data is flagged as a Blocking data gap — required before this candidate can proceed to a formal safety evaluation (S1 stage).)
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine indication is supported by a single small pilot comparative study rather than a registered or completed RCT, and Parecoxib is not currently marketed in Taiwan. Critically, the TFDA label (warnings/contraindications) data gap is classified as Blocking, meaning a rigorous safety assessment cannot yet be performed — this alone is sufficient to hold the candidate regardless of efficacy signal strength.
To proceed, the following is needed:
- Obtain TFDA/SmPC label data (warnings, contraindications) to close the Blocking data gap (DG001)
- Obtain DrugBank/primary literature MOA confirmation (DG002)
- Identify or commission a properly powered RCT in acute migraine (current evidence is a single pilot study, N unspecified)
- Clarify route/formulation fit — Parecoxib is an injectable-only product; feasibility for an outpatient migraine-abortive indication needs explicit assessment
- Note: two other candidates in this pack (headache disorder, rank 5, L3; rheumatoid arthritis, rank 9, L4) sit at the same early “Research Question” stage and warrant the same evidentiary bar before any further action; remaining 6 candidates (L5, Hold) show no supporting literature or trials and are not recommended for further review at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.